ATE317452T1 - Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps - Google Patents

Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps

Info

Publication number
ATE317452T1
ATE317452T1 AT99928180T AT99928180T ATE317452T1 AT E317452 T1 ATE317452 T1 AT E317452T1 AT 99928180 T AT99928180 T AT 99928180T AT 99928180 T AT99928180 T AT 99928180T AT E317452 T1 ATE317452 T1 AT E317452T1
Authority
AT
Austria
Prior art keywords
determination
neurological diseases
treating neurological
bche genotype
bche
Prior art date
Application number
AT99928180T
Other languages
English (en)
Inventor
Pierre Sevigny
Heiko Wiebusch
Keith Schappert
Original Assignee
Nova Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Molecular Inc filed Critical Nova Molecular Inc
Application granted granted Critical
Publication of ATE317452T1 publication Critical patent/ATE317452T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99928180T 1998-06-16 1999-06-16 Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps ATE317452T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8940698P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
ATE317452T1 true ATE317452T1 (de) 2006-02-15

Family

ID=22217467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928180T ATE317452T1 (de) 1998-06-16 1999-06-16 Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps

Country Status (8)

Country Link
US (1) US6291175B1 (de)
EP (1) EP1088104B1 (de)
JP (1) JP2002518022A (de)
AT (1) ATE317452T1 (de)
AU (1) AU4529299A (de)
CA (1) CA2330829C (de)
DE (1) DE69929787T2 (de)
WO (1) WO1999066072A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117840A1 (de) 1998-10-01 2001-07-25 Variagenics, Inc. Verfahren zur erkennung oder behandlung von personen mit einem risiko für neuronale erkrankungen durch die bestimmung von gpiiia or gpiib allelvarianten
CN1531424A (zh) * 2000-11-09 2004-09-22 ����˹��ҩ�﹫˾ Sn-38类脂络合物和应用的方法
US7070973B2 (en) * 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US6989261B2 (en) 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US7049121B2 (en) 2001-12-20 2006-05-23 Applied Molecular Evolution Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2004050041A2 (en) * 2002-12-04 2004-06-17 Applied Molecular Evolution, Inc. Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
GB0323703D0 (en) * 2003-10-09 2003-11-12 Medical Res Council Method
EP2412816B1 (de) 2004-07-26 2014-12-03 Pfenex Inc. Verfahren zur verbesserten Proteinexpression durch Strain-Engineering
EP3223182A1 (de) * 2005-11-29 2017-09-27 Children's Hospital Medical Center Optimierung und individualisierung von medikamentenauswahl und -dosierung
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2615172A1 (de) 2007-04-27 2013-07-17 Pfenex Inc. Schnellscreeningverfahren für Bakterienwirte zur Identifizierung bestimmter Stämme mit verbessertem Ertrag und/oder verbesserter Qualität bei der Expression heterologer Proteine
DK2324126T3 (da) 2008-08-12 2014-06-16 Zinfandel Pharmaceuticals Inc FREMGANGSMÅDE TIL IDENTIFICERING AF Alzheimers SYGDOMSRISIKOFAKTORER
EP3385393A1 (de) * 2017-04-05 2018-10-10 Eckart Schnakenberg In-vitro-verfahren zur diagnose des risikos einer person zur ausbildung eines aerotoxischen syndroms und kit zur durchführung des verfahrens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807671A (en) 1995-01-09 1998-09-15 Yissum Research Development Company Of Hebrew University Of Jerusalem Method of screening for genetic predisposition to anticholinesterase therapy
US6022683A (en) 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
WO1999014367A1 (en) 1997-09-12 1999-03-25 Bristol-Myers Squibb Company Method for determining propensity for developing late-onset alzheimer's disease

Also Published As

Publication number Publication date
EP1088104B1 (de) 2006-02-08
EP1088104A2 (de) 2001-04-04
US6291175B1 (en) 2001-09-18
AU4529299A (en) 2000-01-05
DE69929787T2 (de) 2006-11-09
WO1999066072A3 (en) 2000-08-10
WO1999066072A2 (en) 1999-12-23
CA2330829C (en) 2011-08-02
DE69929787D1 (de) 2006-04-20
CA2330829A1 (en) 1999-12-23
JP2002518022A (ja) 2002-06-25

Similar Documents

Publication Publication Date Title
ATE317452T1 (de) Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
DE69939058D1 (de) Vorrichtung zur behandlung von peripheren gefässerkrankungen
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE411399T1 (de) Behandlung der huntington's krankheit mit epa
DE69612649D1 (de) Indolinonverbindungen zur behandlung von krankheiten
DE69232565D1 (de) Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69822638D1 (de) Heterocyclische vinylether zur behandlung neurologischer krankheiten
DE69838789D1 (de) Verfahren zur behandlung oder prävention der alzheimerischen krankheit
EP0820467A4 (de) Verfahren zur behandlung von augenkrankheiten
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
FR2801794B1 (fr) Procede de determination d'un parametre significatif du progres d'un traitement extracorporel de sang
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
BR0012921A (pt) Compostos calcilìticos
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69519799D1 (de) Verfahren zur herstellung von [s,s]-ethylendiamin-n,n'-dibernsteinsäure
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties